Literature DB >> 17380336

[Immune suppression following perforating keratoplasty].

F Birnbaum1, A Reis, T Reinhard.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17380336     DOI： 10.1007/s00347-007-1515-z

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


× No keyword cloud information.
  8 in total

Review 1.  [Immunomodulation in penetrating keratoplasty. Current status and perspectives].

Authors:  U Pleyer
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

2.  [Current practice of immune prophylaxis and therapy in perforating keratoplasty. A survey of members of the Cornea Section of the German Ophthalmological Society].

Authors:  E Bertelmann; T Reinhard; U Pleyer
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

3.  [Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor].

Authors:  T Reinhard; R Sundmacher; E Godehardt; P Heering
Journal:  Ophthalmologe       Date:  1997-07       Impact factor: 1.059

4.  Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial.

Authors:  A Reis; T Reinhard; A Voiculescu; B Kutkuhn; E Godehardt; H Spelsberg; C Althaus; R Sundmacher
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

5.  Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study.

Authors:  Florian Birnbaum; Daniel Böhringer; Yevgenia Sokolovska; Rainer Sundmacher; Thomas Reinhard
Journal:  Transplantation       Date:  2005-04-27       Impact factor: 4.939

6.  Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial.

Authors:  T Reinhard; A Reis; D Böhringer; M Malinowski; A Voiculescu; P Heering; E Godehardt; R Sunmacher
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2001-06       Impact factor: 3.117

7.  Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study.

Authors:  Thomas Reinhard; Susanne Mayweg; Yewgenia Sokolovska; Berthold Seitz; Hans Mittelviefhaus; Katrin Engelmann; Adina Voiculescu; Erhard Godehardt; Rainer Sundmacher
Journal:  Transpl Int       Date:  2005-06       Impact factor: 3.782

8.  An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty.

Authors:  Florian Birnbaum; Alexander Reis; Daniel Böhringer; Yevgenia Sokolowska; Klaus Mayer; Adina Voiculescu; Michael Oellerich; Rainer Sundmacher; Thomas Reinhard
Journal:  Transplantation       Date:  2006-03-15       Impact factor: 4.939
  8 in total
  2 in total

1.  [Intracameral application of corticosteroids for treating severe endothelial rejection after penetrating keratoplasty].

Authors:  F Birnbaum; P Maier; T Reinhard
Journal:  Ophthalmologe       Date:  2007-09       Impact factor: 1.059

2.  Topical pimecrolimus does not prolong clear graft survival in a rat keratoplasty model.

Authors:  Florian Birnbaum; Johannes Schwartzkopff; Christoph Scholz; Thomas Reinhard
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-21       Impact factor: 3.117
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.